Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more

Oncotarget. 2022 Nov 17:13:1273-1285. doi: 10.18632/oncotarget.28303.


Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies. We reviewed the perspective of MDSCs with emerging evidence in this review. Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs.

Keywords: MDSC; TAM; Treg; cancer; immunosuppression.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases*
  • Female
  • Humans
  • Immunotherapy
  • Infant, Newborn
  • Myeloid Cells
  • Myeloid-Derived Suppressor Cells*
  • Neoplasms* / pathology
  • Pregnancy